Michael D. Offin, MD

Articles by Michael D. Offin, MD

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

ByMichael D. Offin, MD

November 11th 2019

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Dr. Offin on Potential Implications of Introducing Biosimilars Into Oncology

ByMichael D. Offin, MD

October 21st 2019

Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.

Latest Updated Articles

Dr. Offin on Potential Implications of Introducing Biosimilars Into Oncology
October 21st 2019
Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC
November 11th 2019

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

Five Under 5: Top Oncology Videos for the Week of 9/20

FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma